VanEck Associates
BSX icon

VanEck Associates’s Boston Scientific BSX Stock Holding History

VanEck Associates’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.05M Buy
94,958
+6,185
+7% +$336K ﹤0.01% 903
2026
Q1 		$5.57M Buy
88,773
+33,954
+62% +$2.72M ﹤0.01% 780
2025
Q4 		$5.23M Buy
54,819
+1,958
+4% +$192K ﹤0.01% 765
2025
Q3 		$5.16M Buy
52,861
+2,360
+5% +$244K ﹤0.01% 756
2025
Q2 		$5.42M Buy
50,501
+1,081
+2% +$109K 0.01% 697
2025
Q1 		$4.99M Sell
49,420
-9,564
-16% -$963K 0.01% 713
2024
Q4 		$5.27M Buy
58,984
+1,090
+2% +$96K 0.01% 677
2024
Q3 		$5.06M Buy
57,894
+8,882
+18% +$700K 0.01% 639
2024
Q2 		$3.77M Buy
49,012
+2,541
+5% +$186K 0.01% 685
2024
Q1 		$3.18M Sell
46,471
-5,934
-11% -$382K ﹤0.01% 727
2023
Q4 		$3.03M Buy
52,405
+1,659
+3% +$88.6K 0.01% 681
2023
Q3 		$2.68M Sell
50,746
-1,435
-3% -$75.3K 0.01% 673
2023
Q2 		$2.82M Sell
52,181
-254
-0.5% -$13.3K 0.01% 646
2023
Q1 		$2.62M Sell
52,435
-2,752
-5% -$130K 0.01% 632
2022
Q4 		$2.55M Buy
55,187
+1,692
+3% +$73.3K 0.01% 622
2022
Q3 		$2.07M Buy
53,495
+4,910
+10% +$197K 0.01% 637
2022
Q2 		$1.81M Buy
48,585
+1,966
+4% +$80K ﹤0.01% 679
2022
Q1 		$2.06M Sell
46,619
-3,247
-7% -$141K ﹤0.01% 698
2021
Q4 		$2.12M Buy
49,866
+32,844
+193% +$1.38M ﹤0.01% 707
2021
Q3 		$739K Buy
17,022
+1,262
+8% +$55.8K ﹤0.01% 865
2021
Q2 		$674K Sell
15,760
-24
-0.2% -$1.01K ﹤0.01% 870
2021
Q1 		$610K Buy
15,784
+3,887
+33% +$147K ﹤0.01% 823
2020
Q4 		$428K Hold
11,897
– – ﹤0.01% 791
2020
Q3 		$455K Sell
11,897
-513
-4% -$19.8K ﹤0.01% 751
2020
Q2 		$436K Sell
12,410
-7,388
-37% -$266K ﹤0.01% 737
2020
Q1 		$646K Sell
19,798
-17,349
-47% -$678K ﹤0.01% 648
2019
Q4 		$1.68M Buy
37,147
+1,513
+4% +$63.3K 0.01% 543
2019
Q3 		$1.45M Buy
35,634
+2,984
+9% +$126K 0.01% 525
2019
Q2 		$1.4M Buy
32,650
+15,568
+91% +$599K 0.01% 522
2019
Q1 		$656K Buy
+17,082
New +$652K ﹤0.01% 648

Other funds holding BSX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

VanEck Associates's BSX Position: Q2 2026 in Review

VanEck Associates increased its Boston Scientific (BSX) stake by 7% in Q2 2026, buying an estimated $336K and bringing the position to 94,958 shares worth $4.05M. The position accounts for ﹤0.01% of the portfolio, ranked #903.

VanEck Associates first reported a position in BSX in Q1 2019 and has held it in 30 quarters since. The position peaked at $5.57M in Q1 2026. 1,468 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • VanEck Associates held 94,958 shares of Boston Scientific worth $4.05M as of Q2 2026.
  • VanEck Associates bought 6,185 Boston Scientific shares in Q2 2026, an estimated $336K.
  • Boston Scientific made up ﹤0.01% of VanEck Associates's portfolio in Q2 2026, its #903 holding.
  • VanEck Associates first reported a position in Boston Scientific in Q1 2019 and has held it in 30 quarters since.
  • VanEck Associates's Boston Scientific position peaked at $5.57M in Q1 2026.
  • 1,468 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.